Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer - PubMed
3 hours ago
- #DNA damage repair
- #head and neck cancer
- #cisplatin resistance
- ANGPTL4 is a molecular biomarker for oral dysplasia and head and neck squamous cell carcinoma (HNSCC).
- ANGPTL4 interacts with NRP1 to activate pathways that promote HNSCC development and progression.
- ANGPTL4 contributes to cisplatin resistance in HNSCC by enhancing DNA damage response and homologous recombination.
- ANGPTL4 promotes RAD51 phosphorylation at Tyr315/54 via an NRP1/ABL1-dependent mechanism.
- Pharmacological inhibition of NRP1 or ABL1 reverses ANGPTL4-mediated DNA repair, increasing cisplatin-induced cell death in HNSCC models.
- Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis offers a potential therapeutic strategy to overcome cisplatin resistance in HNSCC.